These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35471048)

  • 21. The mouse-canine chimeric anti-dog podoplanin antibody P38B exerts antitumor activity in mouse xenograft models.
    Kato Y; Ohishi T; Kawada M; Maekawa N; Konnai S; Itai S; Yamada S; Kaneko MK
    Biochem Biophys Rep; 2019 Mar; 17():23-26. PubMed ID: 30519645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Defucosylated Monoclonal Antibody (H
    Suzuki H; Ohishi T; Nanamiya R; Kawada M; Kaneko MK; Kato Y
    Curr Issues Mol Biol; 2023 Sep; 45(10):7734-7748. PubMed ID: 37886932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
    Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
    Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor activities against breast cancers by an afucosylated anti-HER2 monoclonal antibody H
    Tanaka T; Suzuki H; Ohishi T; Kaneko MK; Kato Y
    Cancer Sci; 2024 Jan; 115(1):298-309. PubMed ID: 37942574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma.
    Kurai J; Chikumi H; Hashimoto K; Takata M; Sako T; Yamaguchi K; Kinoshita N; Watanabe M; Touge H; Makino H; Igishi T; Hamada H; Yano S; Shimizu E
    Int J Oncol; 2012 Nov; 41(5):1610-8. PubMed ID: 22922885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients.
    Ishiguro T; Kawai S; Habu K; Sugimoto M; Shiraiwa H; Iijima S; Ozaki S; Matsumoto T; Yamada-Okabe H
    Cancer Sci; 2010 Oct; 101(10):2227-33. PubMed ID: 20701608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor activity in breast cancer mouse xenograft models.
    Tanaka T; Ohishi T; Asano T; Takei J; Nanamiya R; Hosono H; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
    Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34013368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma.
    Niwa R; Shoji-Hosaka E; Sakurada M; Shinkawa T; Uchida K; Nakamura K; Matsushima K; Ueda R; Hanai N; Shitara K
    Cancer Res; 2004 Mar; 64(6):2127-33. PubMed ID: 15026353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Humanized and Defucosylated Antibody against Podoplanin (humLpMab-23-f) Exerts Antitumor Activities in Human Lung Cancer and Glioblastoma Xenograft Models.
    Suzuki H; Ohishi T; Kaneko MK; Kato Y
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.
    Kaneko MK; Yamada S; Nakamura T; Abe S; Nishioka Y; Kunita A; Fukayama M; Fujii Y; Ogasawara S; Kato Y
    Cancer Med; 2017 Apr; 6(4):768-777. PubMed ID: 28332312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti‑HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma.
    Asano T; Ohishi T; Takei J; Nakamura T; Nanamiya R; Hosono H; Tanaka T; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
    Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishment of EMab-134, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Detecting Squamous Cell Carcinoma Cells of the Oral Cavity.
    Itai S; Yamada S; Kaneko MK; Chang YW; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Dec; 36(6):272-281. PubMed ID: 29090976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.
    Yang Y; Guo Q; Xia M; Li Y; Peng X; Liu T; Tong X; Xu J; Guo H; Qian W; Hou S; Dai J; Wang H; Liu R; Guo Y
    MAbs; 2015; 7(2):440-50. PubMed ID: 25679409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
    Kaneko MK; Abe S; Ogasawara S; Fujii Y; Yamada S; Murata T; Uchida H; Tahara H; Nishioka Y; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells.
    Miyamoto S; Iwamoto R; Furuya A; Takahashi K; Sasaki Y; Ando H; Yotsumoto F; Yoneda T; Hamaoka M; Yagi H; Murakami T; Hori S; Shitara K; Mekada E
    Clin Cancer Res; 2011 Nov; 17(21):6733-41. PubMed ID: 21918176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of Core-Fucose-Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies.
    Kaneko MK; Ohishi T; Nakamura T; Inoue H; Takei J; Sano M; Asano T; Sayama Y; Hosono H; Suzuki H; Kawada M; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):167-174. PubMed ID: 33085938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A defucosylated anti-PD-L1 monoclonal antibody 13-mG
    Takei J; Ohishi T; Kaneko MK; Harada H; Kawada M; Kato Y
    Biochem Biophys Rep; 2020 Dec; 24():100801. PubMed ID: 32923698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
    Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
    Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity.
    Kubach J; Hubo M; Amendt C; Stroh C; Jonuleit H
    Int J Cancer; 2015 Feb; 136(4):821-30. PubMed ID: 24947844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.